News: Selected items from Google Alert – multiple sclerosis

Teva’s Copaxone Maintains a Dominant Presence in the MS Treatment Algorithm …
MarketWatch (press release)
According to Treatment Algorithms in Multiple Sclerosis, Biogen Idec/Elan’s Tysabri saw little use as a first-line therapy among newly diagnosed patients, consistent with its labeling, but experienced a considerable increase in patient share as a …
See all stories on this topic »

Phase III Data on Sanofi’s Lemtrada
Zacks.com
Results were presented from the phase III CARE-MS I study, which was conducted in patients with relapsing-remitting multiple sclerosis (RRMS). Alemtuzumab met the first primary endpoint of the randomized phase III study. Results showed that treatment …
See all stories on this topic »

Allozyne Looks to Rustle Up Interest on Wall Street With Backdoor IPO
Xconomy
And Allozyne is an unknown quantity to most Wall Street investors—it has an unfamiliar protein engineering technology platform, and a lead drug candidate for multiple sclerosis that’s still in the first of three clinical trial stages normally required …
See all stories on this topic »

Chronic Cerebrospinal Venous Insufficiency and Multiple Sclerosis …
Archives of Neurology, a monthly professional medical journal published by the American Medical Association, publishes original, peer-reviewed scientific …
archneur.ama-assn.org/cgi/content/short/archneurol.2011.179